ALKS
Alkermes plc.
Key Financials
Net Income
$241.7M
↓ 34.2%
Revenue
$1.5B
↓ 5.2%
Operating Income
$254.0M
↓ 39.6%
Total Liabilities
$667.7M
↑ 13.1%
EPS (Diluted)
$1.43
↓ 34.1%
Total Assets
$2.5B
↑ 21.0%
Shareholders' Equity
$1.8B
↑ 24.2%
Cash & Equivalents
$388.6M
↑ 33.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 7/1/2026 | View on SEC |
| 144 | 7/1/2026 | View on SEC |
| 8-K | 6/15/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 144 | 6/12/2026 | View on SEC |
| 4 | 6/4/2026 | View on SEC |
| 144 | 6/4/2026 | View on SEC |
| 4 | 6/1/2026 | View on SEC |
| 144 | 6/1/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ALKS |
| Company Name | Alkermes plc. |
| CIK | 1520262 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 00-353-1-772-8000 |